Summary of findings 16. Safety: eczema ‐ dermatitis.
| Safety: eczema ‐ dermatitis | |||||
| Patient or population: children 9 months to 15 years old Setting: general population Intervention: MMR vaccine Comparison: vaccinated | |||||
| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | № of participants (studies) | Certainty of the evidence (GRADE) | |
| Risk of eczema ‐ dermatitis amongst unvaccinated | Risk of eczema ‐ dermatitis amongst vaccinated | ||||
| Cohort study (rate ratio) | Study population | Rate ratio 3.50 (2.38 to 5.15) | 14,353 (1 observational study) | ⊕⊝⊝⊝ VERY LOW 1 | |
| 0 per 1000 | 0 per 1000 (0 to 0) | ||||
| Cohort study (risk ratio) | Study population | RR 0.75 (0.29 to 1.94) | 555 (1 observational study) | ⊕⊕⊝⊝ LOW | |
| 0 per 1000 | 0 per 1000 (0 to 0) | ||||
| *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; MMR: measles, mumps, rubella vaccine; RR: risk ratio | |||||
| GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | |||||
1Downgraded one level due to ascertainment bias which seriously weakens confidence in the results.